Chapter/Section Purchase

1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Intravenous
1.2.3 Oral
1.2.4 Subcutaneous
1.2.5 Others
1.3 Market by Application
1.3.1 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Perspective (2017-2028)
2.2 Neuromyelitis Optica Spectrum Disorder (NMOSD) Growth Trends by Region
2.2.1 Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Neuromyelitis Optica Spectrum Disorder (NMOSD) Historic Market Size by Region (2017-2022)
2.2.3 Neuromyelitis Optica Spectrum Disorder (NMOSD) Forecasted Market Size by Region (2023-2028)
2.3 Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Dynamics
2.3.1 Neuromyelitis Optica Spectrum Disorder (NMOSD) Industry Trends
2.3.2 Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Drivers
2.3.3 Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Challenges
2.3.4 Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Neuromyelitis Optica Spectrum Disorder (NMOSD) Players by Revenue
3.1.1 Global Top Neuromyelitis Optica Spectrum Disorder (NMOSD) Players by Revenue (2017-2022)
3.1.2 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Market Share by Players (2017-2022)
3.2 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue
3.4 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Concentration Ratio
3.4.1 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue in 2021
3.5 Neuromyelitis Optica Spectrum Disorder (NMOSD) Key Players Head office and Area Served
3.6 Key Players Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Solution and Service
3.7 Date of Enter into Neuromyelitis Optica Spectrum Disorder (NMOSD) Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Neuromyelitis Optica Spectrum Disorder (NMOSD) Breakdown Data by Type
4.1 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Historic Market Size by Type (2017-2022)
4.2 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Forecasted Market Size by Type (2023-2028)
5 Neuromyelitis Optica Spectrum Disorder (NMOSD) Breakdown Data by Application
5.1 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Historic Market Size by Application (2017-2022)
5.2 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size (2017-2028)
6.2 North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type
6.2.1 North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2017-2022)
6.2.2 North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2023-2028)
6.2.3 North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Type (2017-2028)
6.3 North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application
6.3.1 North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2017-2022)
6.3.2 North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2023-2028)
6.3.3 North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Application (2017-2028)
6.4 North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country
6.4.1 North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2017-2022)
6.4.2 North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2023-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size (2017-2028)
7.2 Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type
7.2.1 Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2017-2022)
7.2.2 Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2023-2028)
7.2.3 Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Type (2017-2028)
7.3 Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application
7.3.1 Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2017-2022)
7.3.2 Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2023-2028)
7.3.3 Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Application (2017-2028)
7.4 Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country
7.4.1 Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2017-2022)
7.4.2 Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size (2017-2028)
8.2 Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type
8.2.1 Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Type (2017-2028)
8.3 Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application
8.3.1 Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Application (2017-2028)
8.4 Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Region
8.4.1 Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size (2017-2028)
9.2 Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type
9.2.1 Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2017-2022)
9.2.2 Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2023-2028)
9.2.3 Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Type (2017-2028)
9.3 Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application
9.3.1 Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2017-2022)
9.3.2 Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2023-2028)
9.3.3 Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Application (2017-2028)
9.4 Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country
9.4.1 Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2017-2022)
9.4.2 Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size (2017-2028)
10.2 Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type
10.2.1 Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Type (2017-2028)
10.3 Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application
10.3.1 Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Application (2017-2028)
10.4 Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country
10.4.1 Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 F. Hoffmann-La Roche Ltd
11.1.1 F. Hoffmann-La Roche Ltd Company Details
11.1.2 F. Hoffmann-La Roche Ltd Business Overview
11.1.3 F. Hoffmann-La Roche Ltd Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction
11.1.4 F. Hoffmann-La Roche Ltd Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2017-2022)
11.1.5 F. Hoffmann-La Roche Ltd Recent Developments
11.2 Alexion Pharmaceuticals
11.2.1 Alexion Pharmaceuticals Company Details
11.2.2 Alexion Pharmaceuticals Business Overview
11.2.3 Alexion Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction
11.2.4 Alexion Pharmaceuticals Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2017-2022)
11.2.5 Alexion Pharmaceuticals Recent Developments
11.3 RemeGen
11.3.1 RemeGen Company Details
11.3.2 RemeGen Business Overview
11.3.3 RemeGen Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction
11.3.4 RemeGen Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2017-2022)
11.3.5 RemeGen Recent Developments
11.4 Nihon Pharmaceutical
11.4.1 Nihon Pharmaceutical Company Details
11.4.2 Nihon Pharmaceutical Business Overview
11.4.3 Nihon Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction
11.4.4 Nihon Pharmaceutical Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2017-2022)
11.4.5 Nihon Pharmaceutical Recent Developments
11.5 Harbour BioMed
11.5.1 Harbour BioMed Company Details
11.5.2 Harbour BioMed Business Overview
11.5.3 Harbour BioMed Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction
11.5.4 Harbour BioMed Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2017-2022)
11.5.5 Harbour BioMed Recent Developments
11.6 Lundbeck
11.6.1 Lundbeck Company Details
11.6.2 Lundbeck Business Overview
11.6.3 Lundbeck Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction
11.6.4 Lundbeck Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2017-2022)
11.6.5 Lundbeck Recent Developments
11.7 Bionure
11.7.1 Bionure Company Details
11.7.2 Bionure Business Overview
11.7.3 Bionure Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction
11.7.4 Bionure Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2017-2022)
11.7.5 Bionure Recent Developments
11.8 Opexa Therapeutics
11.8.1 Opexa Therapeutics Company Details
11.8.2 Opexa Therapeutics Business Overview
11.8.3 Opexa Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction
11.8.4 Opexa Therapeutics Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2017-2022)
11.8.5 Opexa Therapeutics Recent Developments
11.9 TG Therapeutics
11.9.1 TG Therapeutics Company Details
11.9.2 TG Therapeutics Business Overview
11.9.3 TG Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction
11.9.4 TG Therapeutics Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2017-2022)
11.9.5 TG Therapeutics Recent Developments
11.10 Bio-Thera Solutions
11.10.1 Bio-Thera Solutions Company Details
11.10.2 Bio-Thera Solutions Business Overview
11.10.3 Bio-Thera Solutions Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction
11.10.4 Bio-Thera Solutions Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2017-2022)
11.10.5 Bio-Thera Solutions Recent Developments
11.11 Boston Pharmaceuticals
11.11.1 Boston Pharmaceuticals Company Details
11.11.2 Boston Pharmaceuticals Business Overview
11.11.3 Boston Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction
11.11.4 Boston Pharmaceuticals Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2017-2022)
11.11.5 Boston Pharmaceuticals Recent Developments
11.12 Cour Pharmaceutical
11.12.1 Cour Pharmaceutical Company Details
11.12.2 Cour Pharmaceutical Business Overview
11.12.3 Cour Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction
11.12.4 Cour Pharmaceutical Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2017-2022)
11.12.5 Cour Pharmaceutical Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer